New findings from a groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial, show no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer.
Dean Tsarwhas, MD, Medical Director, North Region, Cancer Services, Northwestern Memorial Healthcare, joins the podcast to explain these findings and to let women know that this could help identify women with a low risk of recurrence who could be spared chemotherapy.